# Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer

> **NCT07647653** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong University** · enrollment: 120 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib+Bevacizumab
- **DRUG:** Fluzoparib+Bevacizumab

## Key facts

- **NCT ID:** NCT07647653
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2031-02-28
- **Final completion:** 2031-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647653, "Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*